Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California, that specializes in the discovery and development of RNA-targeted therapeutics. The company is recognized for its innovative antisense technology, which enables the creation of drugs for diseases that lack effective treatments. Ionis's product portfolio includes SPINRAZA, approved for spinal muscular atrophy, and TEGSEDI and WAYLIVRA, which target hereditary transthyretin-mediated amyloidosis and familial chylomicronemia syndrome, respectively. The company is advancing a diverse pipeline focused on neurology, cardiovascular, metabolic, and rare diseases, with investigational drugs such as Tominersen for Huntington’s disease and IONIS-GCGRRx for type 2 diabetes. Additionally, Ionis collaborates with major pharmaceutical companies, including AstraZeneca and Biogen, to enhance its research and development efforts. Founded in 1989, Ionis Pharmaceuticals continues to drive innovation in the field of RNA therapeutics.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. .
Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.The company's platform uses biological datasets, human genetics, and programmable biology to power target discovery and development, enabling scientists to systematically generate, interrogate, and prioritize high-confidence therapeutic hypotheses.
Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases. Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people. We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases. We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI motility disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.